Gender parity in African science.

Africa has seen a notable increase in young women's participation in science, technology, engineering, and mathematics (STEM) fields over the past two decades. In 2019, the continent boasted the greatest share of female STEM students globally-47% across 49 universities-according to a report from the United Nations Educational, Scientific and Cultural Organization. Sadly, much of this talent is underutilized. Traditional gender expectations and domestic roles pose substantial obstacles, restricting African women from accessing STEM career opportunities. In sub-Saharan Africa, for example, only 31% of professional researchers are women. Without closing the gender gap in African science, progress on widespread problems such as maternal and child health, and food security, is unlikely.

Diffuse Maculopapular Dermatitis Associated With Leuprorelin Acetate Androgen Deprivation Therapy.

Androgen deprivation therapy (ADT) is one of the effective treatment methods for prostate cancer, often used with radiation therapy. Among the key ADT agents is leuprolide, a synthetic gonadotropin-releasing hormone agonist, which effectively suppresses testosterone production which is a requisite for the growth and division of prostate cancer cells. However, leuprolide is associated with several well-known side effects and less common dermatological reactions. In this case, we present an 80-year-old male patient with stage IIB prostate cancer who developed diffuse maculopapular dermatitis following leuprolide acetate ADT. The patient first experienced mild dermatitis following the fifth monthly 7.5 mg leuprolide injection before it developed into a general body rash after six injections. The dermatitis manifested on the patient's arms, thighs, calves, dorsum, and back of hands but sparing the abdomen, face, and neck. The pruritic dermatitis was managed successfully with a three-week course of prednisone which led to complete resolution without long-term sequelae. This case highlights the importance of recognizing and managing dermatological side effects associated with ADT. Clinicians should maintain an index of suspicion and act promptly when these side effects manifest. Systematic reporting and further research are essential to enhance patient safety and understanding of drug-related dermatological manifestations.